TL;DR
Traditional insurance places risk with a third-party carrier; captive insurance places risk with an entity owned by the insured (or insureds in a group captive). For clinical-stage biotech, traditional D&O and clinical trial liability are typically the right structure given IPO-readiness and investor-mandated coverages. Captive structures make sense for established commercial-stage biotech with retained risk appetite and predictable loss patterns.
Risk financing structure
Captive insurance structures - where the parent operator owns and operates a licensed insurance entity that writes some of the parent\'s coverage - are well-established at scale across many industries. For biotech and life-sciences operators, captives are most often considered at $50M+ revenue with sustained premium spend and predictable loss profile. Below that scale, the formation and operating costs typically outweigh the underwriting and investment-income benefits.
This page covers the practical comparison: when each structure fits, the revenue and complexity thresholds where captives become viable, and the regulatory and sponsor-MSA implications of moving coverage into a captive.
Last updated 2026-05-12
Side-by-side
Frequently asked
Captives typically become viable at $50M+ revenue with sustained insurance spend of $1M+ annually and a sophisticated finance team. Below this scale, formation costs ($75K-$300K) and annual operating costs ($50K-$150K) amortize too slowly to justify. The exception is workers comp deductible buy-back captives which work at smaller scale.
Pure captives do not carry A.M. Best ratings and generally do not satisfy sponsor MSAs that require A- VII or better. The workaround is a fronting arrangement where a Best-rated commercial carrier issues the policy of record and reinsures the risk to the captive. The sponsor sees a Best-rated paper; the operator captures the captive economics.
High-frequency, lower-severity lines work best: workers comp deductible buy-back, auto deductible buy-back, property deductible, environmental impairment with predictable losses. Catastrophic-severity lines like products liability are harder to write in a captive because the parent captive may not have sufficient capital to absorb a tail event; they require careful reinsurance structuring.
Yes, when structured properly. Premium paid to the captive is deductible if the captive meets IRS risk-distribution and risk-shifting tests. Small captives may elect IRS 831(b) treatment (premium income up to $2.8M in 2026 taxed only on investment income, not underwriting income). IRS scrutiny of captives has been heavy in recent years; structure properly with experienced counsel.
6-12 months from feasibility study to first policy. Steps: feasibility study (2-3 months), domicile selection and licensing (3-6 months), initial capitalization, actuarial setup, first policy issuance, and integration with existing program. Operating costs begin accruing from licensure.
Most biotechs do not write D&O in their own captives because the parent-company exposure and individual-director exposure are concentrated in the same place. D&O is typically retained with commercial carriers even when other lines move to captive. Captives can hold deductibles or self-insured retentions under D&O policies, which is more common than full captive participation.
Free coverage review